NewAmsterdam Pharma (NASDAQ:NAMSW) Short Interest Down 40.8% in June

NewAmsterdam Pharma (NASDAQ:NAMSW) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totaling 42 shares, a drop of 40.8% from the May 31st total of 71 shares. Based on an average daily volume of 1,378 shares, the days-to-cover ratio is presently 0.0 days.

Hedge Funds Weigh In On NewAmsterdam Pharma

A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. bought a new stake in NewAmsterdam Pharma (NASDAQ:NAMSW) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 15,708 shares of the company’s stock, valued at approximately $397,000.

NewAmsterdam Pharma Stock Up 10.2%

Shares of NAMSW traded up $2.19 during mid-day trading on Wednesday, hitting $23.55. 1,000 shares of the company were exchanged, compared to its average volume of 1,862. NewAmsterdam Pharma has a 1-year low of $8.41 and a 1-year high of $30.45. The company has a 50 day moving average of $22.13 and a 200-day moving average of $22.22.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.